GABA Therapeutics is a subsidiary of ATAI that is developing a novel GABA modulator for the treatment of mood disorders.
GABA Therapeutics
“GABA Therapeutics is developing GRX-917, an anxiety medication as effective as benzodiazepines like Xanax, but with minimal to no side effects. The drug’s dual mechanism of action may also benefit a broad range of neuropsychiatric and neurological disorders.”
The company predicts that it will take (at least) seven years before a possible drug hits the market.
“Gaba’s executive team formed last August and raised a $15.5 million Series A round from Atai Life Sciences last October.”
News
- Biotech with Anxiety Drug Lands Funding (February 2020)
- GABA Therapeutics receives approval to begin phase I clinical trials (November 2019)
- GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders (September 2019)
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates